Is fotantinib/fotantinib officially launched in China?

As of now, fostamatinib has not yet received formal marketing approval from the National Medical Products Administration in mainland China. Despite this, the introduction of the drug in China is being actively promoted. In 2018, Kissei Pharmaceutical obtained the development and commercialization rights of fotantinib in China and subsequently licensed these rights to Inmagene. Inmagene plans to introduce fotantinib into the Chinese market by accelerating the development and registration process to meet new needs for the treatment of chronic immune thrombocytopenia (ITP).

Fotantinib has been approved in the United States, Europe and Canada for the treatment of adult patients with chronic ITP who have had an inadequate response to previous treatments. The drug reduces the immune system's destruction of platelets by inhibiting spleen tyrosine kinase (SYK), thereby increasing platelet counts and reducing the risk of bleeding. Its unique mechanism of action provides new treatment options for ITP patients, especially those who do not respond well to traditional treatments.

In China, the marketing process of fotantinib may be affected by a variety of factors, including the conduct of clinical trials, the progress of registration applications, and the time for regulatory approval. Currently, there is no public information indicating that fotantinib has been officially launched in mainland China. However, as China continues to optimize the approval process for innovative drugs and the demand for treatment of rare and refractory diseases increases, the prospects for the launch of fotantinib in China are generally optimistic.

For Chinese ITP patients, the introduction of fotantinib will provide more treatment options, especially when existing treatments are ineffective. Patients and medical professionals should pay close attention to the registration and launch of fotantinib in China in order to benefit from the drug in a timely manner once it is approved. At the same time, participating in relevant clinical trials is also a way to obtain treatment opportunities with this drug.

Reference materials:https://go.drugbank.com/drugs/DB12010